FocalTherics at UBS Global Healthcare Conference: growth push

On Tuesday, 10 November 2026, FocalTherics (FOCL) showcased its growth strategy at the UBS Global Healthcare Conference. The company highlighted rising prostate cancer demand, new applications for its ultrasound technology, and a path toward profitability. Management emphasized strong recent sales, improved reimbursement, and expanding clinical evidence, while acknowledging the company's early stage in market adoption.

FocalTherics' revenue grew from EUR 16 million to EUR 26 million in calendar 2024, with a 26% year-over-year increase in HIFU sales. The company aims for a 2025 revenue target of about EUR 55 million, with a three-year compound annual growth rate of around 40% through 2028. Management expects gross margin to reach 60% or more by 2028, leading to break-even operating income and positive EBITDA.

The company is expanding its focus beyond prostate cancer into benign prostatic hyperplasia and deep infiltrating endometriosis. Recent Medicare reimbursement changes and an expanded installed base support the commercial potential, though awareness and adoption are still developing. FocalTherics reported EUR 81.3 million in revenue over the last twelve months in Q3 2026, representing a 94% year-over-year growth. However, the current gross margin of 45% remains below the company's 60% target for 2028.

In 2024, revenue increased from EUR 16 million to EUR 26 million, with HIFU revenue growing by 26% year-over-year. System sales rose by 17% in the latest quarter, and U.S. procedure volumes increased by 32%. Management's growth model targets about EUR 55 million in 2025, which represents a 38% year-over-year increase. The company's 40% compound annual revenue growth projection through 2028 is part of their long-term plan.

FocalTherics' Focal One Robotic HIFU platform is the core of their business, with an installed base of 192 systems, including 94 outside the United States. The company operates at 316 treatment clinical sites globally, with a presence at major U.S. centers like Mayo Clinic, Cleveland Clinic, Memorial Sloan Kettering, and MD Anderson. Hospitals such as 16 University of California teaching hospitals, Kaiser Permanente, and 16 integrated delivery networks now use the platform.

FocalTherics is moving from focusing on academic centers to community hospitals, with younger urologists trained on Focal One aiding this shift. The company also highlighted markets in France, India, Brazil, Latin America, and the Asia-Pacific region. Management emphasized the company's five-axis robotic positioning system and remote connectivity features, including tele-mentoring and remote service support.

The company's success includes treating a Cleveland Clinic patient remotely from Cleveland Clinic Abu Dhabi, about 7,000 miles away. FocalTherics is also developing histotripsy and has filed related patents. The company's long-term strategy focuses on accelerating commercial growth, expanding into new indications, and continuing technology development. The market capitalization stands at $166 million, with a current ratio of 2.63, indicating strong liquidity.